Explore our approved radioligand therapy and imaging products
This site is intended for healthcare professionals outside of the United States (US) and the United Kingdom (UK).
This site is created and funded by Novartis.
Radioligand therapy (RLT) stands at the forefront of modern cancer treatment, offering hope to patients through targeted nuclear medicine
RLT is a treatment method for certain types of cancers that utilizes radioisotopes and cell-targeting compounds, or ligands, to deliver radiation directly to cancer cells.
RLT uses molecules that are beta- or alpha-emitters, as this radiation has the potential to damage and kill target cells with the goal of limiting the damage to nearby healthy cells.1a
PLUVICTOⓇ for progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)2a
PLUVICTOⓇ (lutetium (177Lu) vipivotide tetraxetan) is a PSMA-targeted radioligand therapy that delivers DNA-breaking radiation directly to PSMA-positive bone, nodal, and visceral metastases 2b 3a 4 PLUVICTOⓇ targets PSMA-positive cells, including prostate cancer cells.2c 3b
In the European Union, PLUVICTOⓇ in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.2d
PLUVICTOⓇ (lutetium (177Lu) vipivotide tetraxetan) is a PSMA-targeted radioligand therapy that delivers DNA-breaking radiation directly to PSMA-positive bone, nodal, and visceral metastases 2b 3a 4 PLUVICTOⓇ targets PSMA-positive cells, including prostate cancer cells.2c 3b
In the European Union, PLUVICTOⓇ in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.2d
LUTATHERAⓇ for neuroendocrine tumors (NETs)
LUTATHERAⓇ (lutetium (177Lu) oxodotreotide) is a peptide receptor radionuclide therapy (PRRT). It is composed of the radionuclide lutetium-177 (77Lu) and the somatostatin analogue oxodotreotide that targets somatostatin receptor-positive cells, including neuroendocrine tumor cells. 1b 5 6a
In the European Union, LUTATHERAⓇ is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.6b
LUTATHERAⓇ (lutetium (177Lu) oxodotreotide) is a peptide receptor radionuclide therapy (PRRT). It is composed of the radionuclide lutetium-177 (77Lu) and the somatostatin analogue oxodotreotide that targets somatostatin receptor-positive cells, including neuroendocrine tumor cells. 1b 5 6a
In the European Union, LUTATHERAⓇ is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.6b
Radioligand imaging delivers early and precise disease detection
Radioligand imaging (RLI) is a medical imaging technique that is used to visualize tumor cells with the help of specific molecular targets, such as receptors and proteins within the body.1c 7a
Radioligands use biomarkers that are overexpressed on cancer cells compared with healthy cells and are used to locate tumor cells. RLI may be helpful for determining the disease stage, therapy selection, and treatment monitoring. RLI uses β+ or gamma-emitters, so the radioligand can be located using gamma cameras, single-photon emission computed tomography, or positron emission tomography (PET).1d 7b
LOCAMETZⓇ for the detection of PSMA-positive lesions in prostate cancer 8a
LOCAMETZⓇ is a kit for the radiopharmaceutical preparation of gallium (68Ga) gozetotide.8b This medicinal product is for diagnostic use only. In the European Union, LOCAMETZⓇ, after radiolabelling with gallium-68, is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings 8c :
- Primary staging of patients with high-risk PCa prior to primary curative therapy.
- Suspected PCa recurrence in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy
- Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated
Using LOCAMETZⓇ may help you determine if your patient is eligible for PSMA-targeted radioligand therapy.8d
LOCAMETZⓇ is a kit for the radiopharmaceutical preparation of gallium (68Ga) gozetotide.8b This medicinal product is for diagnostic use only. In the European Union, LOCAMETZⓇ, after radiolabelling with gallium-68, is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings 8c :
- Primary staging of patients with high-risk PCa prior to primary curative therapy.
- Suspected PCa recurrence in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy
- Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated
Using LOCAMETZⓇ may help you determine if your patient is eligible for PSMA-targeted radioligand therapy.8d
NETSPOTⓇ for the detection of somatostatin receptor-positive neuroendocrine tumors 9a
NETSPOTⓇ is a kit containing non-radioactive components used to prepare a radiopharmaceutical product using gallium (68Ga) chloride solution before it is administered intravenously.9b
In Switzerland, after radiolabelling with gallium-68, NETSPOTⓇ is indicated for use as a radioactive diagnostic agent in positron emission tomography imaging to localize somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients.9c
NETSPOTⓇ is a kit containing non-radioactive components used to prepare a radiopharmaceutical product using gallium (68Ga) chloride solution before it is administered intravenously.9b
In Switzerland, after radiolabelling with gallium-68, NETSPOTⓇ is indicated for use as a radioactive diagnostic agent in positron emission tomography imaging to localize somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients.9c
SomaKit TOCⓇ for imaging of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)10a
SomaKit TOCⓇ is a 40-microgram kit for the radiopharmaceutical preparation of gallium (68Ga) edotreotide solution for injection.10b
This medicinal product is for diagnostic use only.10c
In the European Union, after radiolabelling with gallium-68 (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for PET imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated GEP-NETs for localizing primary tumors and their metastases.10d
SomaKit TOCⓇ is a 40-microgram kit for the radiopharmaceutical preparation of gallium (68Ga) edotreotide solution for injection.10b
This medicinal product is for diagnostic use only.10c
In the European Union, after radiolabelling with gallium-68 (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for PET imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated GEP-NETs for localizing primary tumors and their metastases.10d
Our all-encompassing service designed to simplify the adoption of RLT and minimize time to treatment
Explore radioligand therapy
References
1a 1b 1c 1d Yordanova A, Eppard E, Kürpig S, et al. Theranostics in nuclear medicine practice. Onco Targets Ther. 2017;10:4821-4828. doi:10.2147/OTT.S140671
2a 2b 2c 2d Pluvicto (lutetium Lu 177 vipivotide tetraxetan). Summary of product characteristics. Advanced Accelerator Applications (Italy) S.R.L. Accessed July 19, 2024. https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf
3a 3b Ruigrok EAM, van Vliet N, Dalm SU, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48(5):1339-1350. doi:10.1007/s00259-020-05057-6.
4 Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322.
5 Hennrich U, Kopka K. Lutathera®: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel). 2019;12(3):114. doi:10.3390/ph12030114
6a 6b Lutathera (lutetium Lu 177 dotatate). Summary of product characteristics. Advanced Accelerator Applications (Italy) S.R.L. Accessed July 19, 2024. https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf
7a 7b van der Heide CD, Dalm SU. Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. Eur J Nucl Med Mol Imaging. 2022;49(13):4616-4641. doi:10.1007/s00259-022-05870-1
8a 8b 8c 8d Locametz (kit for the preparation of gallium Ga 68 gozetotide injection). Summary of product characteristics. Advanced Accelerator Applications (Italy) S.R.L. Accessed July 19, 2024. https://www.ema.europa.eu/en/documents/product-information/locametz-epar-product-information_en.pdf
9a 9b 9c Netspot (gallium Ga 68 dotatate injection). Switzerland summary of product characteristics. Advanced Accelerator Applications (Italy) S.R.L. Accessed July 19, 2024. https://swissmedicinfo.ch/showText.aspx?textType=FI&lang=EN&authNr=66611&supportMultipleResults=1
10a 10b 10c SomaKit TOC (edotreotide). Summary of product characteristics. Advanced Accelerator Applications (Italy) S.R.L. Accessed July 19, 2024. https://www.ema.europa.eu/en/documents/product-information/somakit-toc-epar-product-information_en.pdf
Get in touch
Our dedicated RLT specialist teams aim to streamline care coordination and alleviate uncertainty, ensuring you and your patients feel confident and supported every step of the way.